Mahmut BÜYÜKŞİMŞEK, Mustafa TOĞUN, Abdullah Evren YETİŞİR, Cem MİRİLİ, Ali OĞUL, Mert TOHUMCUOĞLU, Semra PAYDAŞ

LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ

Amaç: Kemoterapi sırasında hepatit enfeksiyonu reaktivasyonu lenfoma hastalarında önemli bir sorundur. Merkezimizde tedavi edilen lenfoma hastalarında hepatit B virüsü (HBV) ve hepatit C virüsü (HCV) sıklığını araştırmayı amaçladık. Materyal ve Metot: Merkezimizde 2011-2018 yılları arasında tedavi edilen non-hodgkin lenfoma (NHL) ve hodgkin lenfoma (HL) hastalarının dosyaları retrospektif olarak incelendi. Hastaların HBsAg, Anti-HBs, Anti-HBc ve Anti-HCV parametreleri değerlendirildi. Bulgular: 240 NHL hastasının 21' inde (% 8.7) HBsAg antijeni pozitifti. 9 hastada (% 3.7) Anti-HCV pozitifliği tespit edildi. 79 hastada (%33) HBsAg (-), Anti-HBs (+) ve Anti-HBc (+) saptandı ve geçirilmiş hepatit B enfeksiyonu olarak değerlendirildi. 110 HL hastasının 10’ unda (%9.1) HBsAg, 3’ünde (%2.7) Anti-HCV pozitif saptandı. 29 hastada ise (%26.4) HBsAg(-), Anti-HBs(+), Anti-HBc (+) idi ve geçirilmiş hepatit B enfeksiyonu lehine değerlendirildi. HBsAg ve Anti-HCV pozitiflik oranları açısından NHL ve HL hasta grupları karşılaştırıldığında istatiksel anlamlı fark yoktu (p değerleri sırasıyla 0.9 ve 0.63 idi). Sonuç: Lenfoma hastalarında ülkemiz verilerine göre HBV ve HCV pozitifliğinin yüksek olduğu belirlenmiştir. Bölgemizdeki Hepatit B ve C pozitifliği önemli bir sorun teşkil etmektedir. Aşılama ve korunma yöntemleri hakkında gerekli bilgiler sağlanmalıdır.

Evaluation of the Prevalence of Hepatitis B and C in Patients with Lymphoma

Aim: Hepatitis enfection reactivation during chemotherapy is a major problem in lymphoma patients. We aimed to investigate the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in lymphoma patients treated in our center. Materials and Methods: The files of non-hodgkin lymphoma (NHL) and hodgkin lymphoma (HL) patients treated in our center between 2011-2018 were retrospectively reviewed. HBsAg, Anti-HBs, Anti-HBc and Anti-HCV parameters of the patients were evaluated. Results: In 21 (8.7%) of the 240 NHL patients, HBsAg antigen was positive. Anti-HCV positivity was detected in 9 patients (3.7%). In 79 (33%) patients, HBsAg (-), Anti-HBs (+) and Anti-HBc (+) were detected and evaluated as previous hepatitis B infection. In 10 (9.1%) of the 110 HL patients, HBsAg was positive and Anti-HCV positivity was detected in 3 patients (2.7%). In 29 (26.4%) patients, HBsAg (-), Anti-HBs (+) and Anti-HBc (+) were detected and evaluated as previous hepatitis B infection. When HBsAg and Anti-HCV positivity rates were compared between NHL and HL patient groups, no statistically significant difference was detected (p values were 0.9 and 0.63, respectively). Conclusion: According to the data of our country higher positivity of HBV and HCV was determined in lymphoma patients. Hepatitis B and C positivity in our region poses an important problem. Necessary information about vaccination and prevention methods should be provided.

PDF

___

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
2. Alexander DD, Mink PJ, Adami H-O, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:1–39.
3. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
4. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among nonHodgkin lymphoma subtypes: the InterLymph NonHodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):130–44.
5. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta- analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078–85.
6. Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013;37:1107–15.
7. Kim JH, Bang Y-J, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res. 2002;93:471–7.
8. Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica. 2004;89(1):70-6.
9. Altıntaş A, Kaplan MA, Çil T, Yılmaz Ş, Bayan K, Danış R, et al. Hepatitis B virus infection in patient with Hodgkin’s and non-Hodgkin’s lymphoma and clinical significance. Int J Hematol. 2007;17(1):1-6.
10. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156-66.
11. Bayrak S, Güneş ME, Tekeşin K, Akar E, Tural D. Viral Hepatitis Prevalance and Reactivation Rates in Gastrointestinal Cancers. Bakırköy Tıp Dergisi. 2018;14:394-7.
12. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026.
13. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270–5.
14. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147–53.
15. Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut. 2010;59:1430– 45.
16. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta- analysis. J Clin Virol. 2013;57:209–14.